Piper Sandler analyst David Amsellem raised the firm’s price target on Avadel Pharmaceuticals to $18 from $13 and keeps an Overweight rating on the shares post the Q2 report. The analyst cites strong early color on Lumryz commercial dynamics for the target raise.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on AVDL:
- Avadel Pharmaceuticals reports Q2 EPS (83c), consensus (38c)
- Avadel Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2023 Financial Results
- Is AVDL a Buy, Before Earnings?
- Avadel Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
- Needham healthcare/neuroscience analyst holds analyst/industry conference call